NBSE logo

NeuBase Therapeutics Inc

NBSE

$0.86

+ $0.21 (31.04%) This month

Closed: 1 Mar 2024 21:00 US/Eastern

Key details

CEO

Dietrich Stephan

Employees

26

Headquarters

Pittsburgh, US

Sector

Manufacturing

Industry

Pharmaceutical Preparation Manufacturing

About NeuBase Therapeutics Inc

neubase has developed a modular antisense technology platform with the capability to address any rare genetic disease caused by mutant proteins with a single, cohesive approach. neubase's platform improves upon gene silencing therapies by combining the advantages of synthetic approaches with the precision of antisense technologies. neubase plans to use its unparalleled antisense platform to address both repeat expansion disorders, with an initial focus on huntington's disease and myotonic dystrophy, and dominant genetic disorders.

Please treat this data as an indicator only since we can't always guarantee that it's accurate or complete. Bear in mind too that the prices you'll see are delayed by at least 15 minutes. Intraday pricing and company data provided by IEX.
Finimize
© Finimize Ltd. 2023. 10328011. 280 Bishopsgate, London, EC2M 4AG